https://www.selleckchem.com/pr....oducts/sch-527123.ht
HDR-BT boost may be more beneficial than contemporary EBRT boost in selected patients with CC.Recurrence and progression of non-muscle-invasive bladder cancer (NMIBC), frequent despite the availability of multiple treatment modalities, may be partly explained by the presence of immunosuppressive cell populations. We hypothesized that progression of disease could be prevented by the administration of an activated T cell immunotherapy (ACT) at time points when immunosuppressive populations increased in peripheral blood. In an N-of-1 st
Like
Comment
Share
